Table 3:

Fixed-effect cause-specific proportional hazards regression analysis for VTE events within two years pre-and post-immune checkpoint inhibitors

	Entire Cohort (n=2854)		Patients who are alive at 6 months’ post immune checkpoint inhibitors (n=2287)		Patients who are alive at 1 year post immune checkpoint inhibitors (n=2077)		Patients who are alive and have not been lost to follow up at 2 years post immune checkpoint inhibitors (n=754)
	Hazard ratio (95% confidence Interval)	P value	Hazard ratio (95% confidence Interval)	P value	Hazard ratio (95% confidence Interval)	P value	Hazard ratio (95% confidence Interval)	P value
Deep Vein Thrombosis	5.70 (3.79, 8.59)	<0.001	4.58 (2.99, 7.00)	<0.001	4.04 (2.61, 6.26)	<0.001	5.73 (3.13, 9.92)	<0.001
Pulmonary Embolism	4.75 (3.20, 7.10)	<0.001	3.76 (2.50, 5.66)	<0.001	3.18 (2.08, 4.86)	<0.001	4.47 (2.64, 7.56)	<0.001
Venous Thromboembolism	4.98 (3.65, 6.79)	<0.001	3.98 (2.89, 5.48)	<0.001	3.49 (2.51, 4.86)	<0.001	4.89 (3.26, 7.35)	<0.001